Here, the efficacies for reducing cancer cell characteristics of the two new engineered viruses (AAT and shRNA) were evaluated and compared with the HMGA1 sequestration virus (HBS) in three different human pancreatic cancer cell lines (primary focus) and one human breast cancer cell line (to test generality with one non pancreatic cancer cell line) using in vitro viability, toxicity and necrosis assays. The gene discussed is HMGA1; the disease is pancreatic neoplasm.